Ylikorkala O, Kivinen S, Kauppila A
Acta Endocrinol (Copenh). 1980 Apr;93(4):413-8. doi: 10.1530/acta.0.0930413.
Thirteen puerperal women with insufficient lactation were treated with thyrotrophin releasing hormone (TRH) 20 mg twice daily for two weeks. Intravenous (iv) TRH stimulation tests were done before the TRH therapy and within 3-5 h after the last dose of oral TRH. Plasma samples were assayed for prolactin (Prl), thyrotrophin (TSH), triiodothyronine (T3) and thyroxine (T4) by radioimmunoassays, and the lactational response was objectively monitored in 11 women. Oral TRH treatment was associated with significantly (P less than 0.05) depressed Prl levels (23.0 +/- 7.9 microgram/l vs. 61.4 +/- 26.2, mean +/- SEM), no change in TSH levels (3.7 +/- 0.4 IU/l vs. 4.0 +/- 0.4) but significantly (P less than 0.01) elevated T3 (2.17 +/- 1.14 nmol/l vs. 1.83 +/- 0.09) and T4 (131.6 +/- 7.9 nmol/l vs. 96.6 +/- 5.8) levels. Oral TRH entirely blocked the TSH response and significantly (P less than 0.01) blunted the Prl response to iv TRH stimulation. No improvement in lactation was observed.
13名产后泌乳不足的妇女接受促甲状腺激素释放激素(TRH)治疗,剂量为每日2次,每次20mg,共治疗2周。在TRH治疗前以及末次口服TRH后3 - 5小时进行静脉注射(iv)TRH刺激试验。采用放射免疫分析法测定血浆样本中的催乳素(Prl)、促甲状腺激素(TSH)、三碘甲状腺原氨酸(T3)和甲状腺素(T4),并对11名妇女的泌乳反应进行客观监测。口服TRH治疗后,Prl水平显著降低(P < 0.05)(23.0±7.9μg/L对61.4±26.2,均值±标准误),TSH水平无变化(3.7±0.4IU/L对4.0±0.4),但T3(2.17±1.14nmol/L对1.83±0.09)和T4(131.6±7.9nmol/L对96.6±5.8)水平显著升高(P < 0.01)。口服TRH完全阻断了TSH反应,并显著(P < 0.01)减弱了Prl对静脉注射TRH刺激的反应。未观察到泌乳情况改善。